EA200100264A1 - Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly - Google Patents

Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly

Info

Publication number
EA200100264A1
EA200100264A1 EA200100264A EA200100264A EA200100264A1 EA 200100264 A1 EA200100264 A1 EA 200100264A1 EA 200100264 A EA200100264 A EA 200100264A EA 200100264 A EA200100264 A EA 200100264A EA 200100264 A1 EA200100264 A1 EA 200100264A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cys
thr
val
gly
ser
Prior art date
Application number
EA200100264A
Other languages
English (en)
Inventor
Джорж Тучинский
Тэффи Уильямс
Original Assignee
Филадельфия Хеалс Энд Эдьюкейшн Корпорейшн
Инкин Фармасьютикал Компани, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Филадельфия Хеалс Энд Эдьюкейшн Корпорейшн, Инкин Фармасьютикал Компани, Инк. filed Critical Филадельфия Хеалс Энд Эдьюкейшн Корпорейшн
Publication of EA200100264A1 publication Critical patent/EA200100264A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

В настоящем изобретении предложена последовательность клеточного матриксного рецептора, специфического для области тромбоспондина Cys-Ser-Val-Thr-Cys-Gly (последовательность № 1). Предложены также способы очистки, клонирования и экспрессии. Рецепторный протеин находит применение при диагностике, профилактике и терапии рака.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100264A 1999-06-21 2000-06-21 Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly EA200100264A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14030999P 1999-06-21 1999-06-21
US17662600P 2000-01-19 2000-01-19
PCT/US2000/016953 WO2001005968A1 (en) 1999-06-21 2000-06-21 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor

Publications (1)

Publication Number Publication Date
EA200100264A1 true EA200100264A1 (ru) 2001-10-22

Family

ID=26838062

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100264A EA200100264A1 (ru) 1999-06-21 2000-06-21 Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly

Country Status (10)

Country Link
US (1) US20030180295A1 (ru)
EP (1) EP1109900A1 (ru)
JP (1) JP2004513066A (ru)
KR (1) KR20010072825A (ru)
CN (1) CN1335887A (ru)
AU (1) AU5627000A (ru)
CA (1) CA2340721A1 (ru)
EA (1) EA200100264A1 (ru)
MX (1) MXPA01001885A (ru)
WO (1) WO2001005968A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078359A2 (en) * 1999-06-21 2000-12-28 George Tuszynski Compositions for treating chemotherapy-resistant tumor cells
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
ATE358136T1 (de) * 2002-10-23 2007-04-15 Ct For Res And Technology Hell Prionen-bindende peptidsequenzen
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
WO2005094422A2 (en) * 2004-02-20 2005-10-13 Kevin Jon Williams Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases
EP2015767B1 (en) * 2006-04-27 2016-01-06 Lantmännen AS-Faktor AB Use of antisecretory factor for treating intraocular hypertension
EP2086566A2 (en) * 2006-10-10 2009-08-12 Squicor Compositions and methods for treating and diagnosing cancers
WO2010065342A1 (en) 2008-11-25 2010-06-10 Temple University Angiocidin inhibition of tumor cell growth
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
SG2013090626A (en) * 2013-12-06 2015-07-30 Mastercard Asia Pacific Pte Ltd System and method for conducting a transaction using a fuel dispensing nozzle
EP3116895A4 (en) * 2014-03-12 2017-08-16 Temple University Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
UA126146C2 (uk) 2015-09-18 2022-08-25 Арч Онколоджі, Інк. Терапевтичне антитіло до cd47
CN106885908B (zh) * 2015-12-23 2019-05-07 中国人民解放军第二军医大学 血清psmd4蛋白的检测试剂盒及其检测方法与应用
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565789A (en) * 1983-04-04 1986-01-21 The United States Of America As Represented By The Department Of Health And Human Services Cell matrix receptor system and use in cancer diagnosis and management
US5190920A (en) * 1990-09-24 1993-03-02 W. R. Grace & Co.-Conn. Method for using synthetic analogs of thrombospondin for inhibiting metastasis activity
US5367059A (en) * 1992-05-14 1994-11-22 W. R. Grace & Co.-Conn. Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor
GB9509957D0 (en) * 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
NZ331866A (en) * 1996-03-15 2000-05-26 Corixa Corp Compounds for immunotherapy and immunodiagnosis of prostate cancer

Also Published As

Publication number Publication date
CN1335887A (zh) 2002-02-13
KR20010072825A (ko) 2001-07-31
AU5627000A (en) 2001-02-05
JP2004513066A (ja) 2004-04-30
MXPA01001885A (es) 2002-04-24
WO2001005968A1 (en) 2001-01-25
EP1109900A1 (en) 2001-06-27
WO2001005968A9 (en) 2001-05-03
CA2340721A1 (en) 2001-01-25
US20030180295A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
PT93167A (pt) Novo anticorpo monoclonal contra novo antigenio associado a tumores humanos
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DE68928069T2 (de) Anti-T-Zell Rezeptordeterminanten zur Behandlung von Autoimmunkrankheiten
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DK0770089T3 (da) Vækstdifferentieringsfaktor-12
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
GB9924957D0 (en) Novel treatment
ATE120372T1 (de) Antikörper für die antilymphozyten- antikörpertherapie.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE69728897D1 (de) Saeugetierchemokine
DE69825629D1 (de) Säugertier edg-7 rezeptor homologen
DK0939769T3 (da) Vertebrat-Smoothened-proteiner